249 related articles for article (PubMed ID: 23754386)
1. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase.
Sutto L; Gervasio FL
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10616-21. PubMed ID: 23754386
[TBL] [Abstract][Full Text] [Related]
2. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
Dixit A; Verkhivker GM
PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203
[TBL] [Abstract][Full Text] [Related]
3. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Park J; McDonald JJ; Petter RC; Houk KN
J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
Tamirat MZ; Koivu M; Elenius K; Johnson MS
PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
[TBL] [Abstract][Full Text] [Related]
5. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants.
Saldaña-Rivera L; Bello M; Méndez-Luna D
J Biomol Struct Dyn; 2019 Oct; 37(17):4671-4684. PubMed ID: 30558477
[TBL] [Abstract][Full Text] [Related]
6. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by
Ruan Z; Kannan N
Proc Natl Acad Sci U S A; 2018 Aug; 115(35):E8162-E8171. PubMed ID: 30104348
[TBL] [Abstract][Full Text] [Related]
7. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
8. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
9. Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis.
Bello M
Int J Biol Macromol; 2018 Oct; 118(Pt B):1948-1962. PubMed ID: 30017980
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
Ding X; Liu X; Song X; Yao J
Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
[TBL] [Abstract][Full Text] [Related]
13. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Yun CH; Mengwasser KE; Toms AV; Woo MS; Greulich H; Wong KK; Meyerson M; Eck MJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2070-5. PubMed ID: 18227510
[TBL] [Abstract][Full Text] [Related]
14. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
[TBL] [Abstract][Full Text] [Related]
15. Effects of Single Nucleotide Polymorphisms on the Binding of Afatinib to EGFR: A Potential Patient Stratification Factor Revealed by Modeling Studies.
Kannan S; Tan DS; Verma CS
J Chem Inf Model; 2019 Jan; 59(1):309-315. PubMed ID: 30481018
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of the effect of activating mutations on the EGF receptor.
Galdadas I; Carlino L; Ward RA; Hughes SJ; Haider S; Gervasio FL
Elife; 2021 Jul; 10():. PubMed ID: 34319231
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
19. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.
Li M; Guo J
ACS Chem Neurosci; 2021 Feb; 12(3):462-472. PubMed ID: 33435671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
